DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/a8463819/nasopharyngeal_can) has announced the addition of GlobalData's new report "Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global nasopharyngeal cancer therapeutics market. The report identifies the key trends shaping and driving the global nasopharyngeal cancer therapeutics market. It also provides insights into the current competitive landscape and the emerging players expected to significantly alter the market positions of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global nasopharyngeal cancer therapeutics sector.
GlobalData estimates that the global (the seven key markets of the US, the UK, Germany, Italy, France, Spain and Japan) nasopharyngeal cancer therapeutics market was valued at $53.0m in 2011 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 0.5% to reach $55.0m by 2019. The existing market is strong, and is represented by three approved products - Erbitux (cetuximab), Taxotere (docetaxel) and Blenoxane (bleomycin), of which only the former is patent protected. Erbitux is currently approved in the US and European Union (EU) but not in Japan. The growth during 2006-2011 is primarily attributed to launch of Taxotere and Erbitux for the treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Key Topics Covered:
1 List of Tables and Figures
2 Nasopharyngeal Cancer Therapeutics - Introduction
3 Nasopharyngeal Cancer Therapeutics - Market Characterization
4 Nasopharyngeal Cancer Therapeutics Market - Competitive Assessment
5 Nasopharyngeal Cancer Therapeutics Market - Pipeline Assessment
6 Nasopharyngeal Cancer Therapeutics - Clinical Trials Mapping
7 Nasopharyngeal Cancer Therapeutics - Strategic Assessment
8 Global Nasopharyngeal Cancer Therapeutics - Future Players in The Market
9 Nasopharyngeal Cancer Therapeutics - Appendix
Companies Mentioned
- Cyclacel Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd.
For more information visit http://www.researchandmarkets.com/research/a8463819/nasopharyngeal_can
Source: GlobalData